Gilead's Hepatitis C Treatment Sofosbuvir Gets European Commission Nod
Gilead Sciences’ Sofosbuvir, a hepatitis C treatment potentially faster and more effective than current therapies, has been approved by the European Commission. The European Commission approval predicates marketing rights for Gilead in all European Union countries including European Economic Area countries Iceland, Norway, and Liechtenstein.
Publication date: Available online 10 October 2020Source: Journal of Clinical and Experimental HepatologyAuthor(s): Pramod Kumar, Anand Kulkarni, Mithun Sharma, Padaki Nagaraja Rao
Authors: Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K Abstract BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients (≥ 75-years-old) compared to nonelderly patients, we conducted a post-marketing prospective cohort study. METHODS: We treated 265 patients with ge...
CONCLUSION: DAAs are effective and safe in the treatment of recurrent HCV infection in LT recipients with history of HCC. Relapse to pre- and post-LT DAA therapy is associated with post-transplantation HCC recurrence. PMID: 33033569 [PubMed]
Publication date: 10–16 October 2020Source: The Lancet, Volume 396, Issue 10257Author(s): Talha Burki
ConclusionsThe study confirmed significant changes in the HCV genotypes partition with G3 genotype rapidly increasing in both countries, with possible impact on the WHO eradication initiative and treatment selection.
Harvey J. Alter, Michael Houghton, and Charles M. Rice awarded for their work
Publication date: Available online 9 October 2020Source: Arab Journal of GastroenterologyAuthor(s): Shereen M. Galal, Shaban M. Soror, Omima Hussien, Ehab F. Moustafa, Sahar M Hassany
Authors: Lembke A PMID: 33028468 [PubMed - in process]
Authors: Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M Abstract People who use drugs (PWUD) face concurrent public health emergencies from overdoses, HIV, hepatitis C, and COVID-19, leading to an unprecedented syndemic. Responses to PWUD that go beyond treatment--such as decriminalization and providing a safe supply of pharmaceutical-grade drugs--could reduce impacts of this syndemic. Solutions already implemented for COVID-19, such as emergency safe-supply prescribing and providing housing to people experiencing homelessness, must be sustained once COVID-19 is contained. This pandemic is not o...
We report a rare case of HBV reactivation in a patient with HCV infection after DAA therapy. Patient concerns: In 1996, a 53-year-old female was identified as infected with HCV at a medical check-up, following which she visited our hospital. She was infected with HCV genotype 2b, and at follow up in 1997, was found to be hepatitis B surface antigen (HBsAg) and antibody against HBsAg negative, antibody against HBV core positive. She then experienced malignant lymphoma in 2001 at 58 years of age. Complete remission was achieved following chemotherapy and autologous peripheral blood stem cell transplantation. In 2014, she ...